Amyris, Inc. has announced it has expanded its existing production contract agreement with ADL Bionatur Solutions, through its fermentation division ADL Biopharma.
Amyris specializes in the development and production of fermentation-derived ingredients for health and wellness, clean beauty and flavors and fragrances markets. ADL Bionatur provides research and development of health products, services and industrial fermentation production, with contract manufacturing capabilities. This marks the second expansion of an agreement the parties executed in 2018.
“We are very pleased with the production quality and cost we’ve achieved and our ability to access sugarcane-based feedstock for our fermentation capacity at ADL in Spain. This asset combined with our expanded access to the DSM-owned Brotas facility enables us the flexibility to meet growing demand from our customers. With a significant volume of ingredients produced at this site during the second half we can confirm no expected negative change to our gross margin target as a result of this expansion,” said Eduardo Alvarez, Amyris chief operating officer.
“This exponential growth of our turnover associated with new contracts, demonstrates the behavior of the demand for these types of products in the market,” said Pilar de la Huerta, CEO of ADL Bionatur Solutions. “It reinforces our sales targets for 2018, which we maintain at around double of our turnover in 2017. Currently, the company has already committed more than 85% of its fermentation capacity for the next two years for our customers.”
